Compass Therapeutics (CMPX)
NASDAQ:CMPX
Top Page
Compass Therapeutics
(NASDAQ:CMPX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▲(7.84% Upside)
Action:ReiteratedDate:03/05/26
The score is primarily shaped by weak operating fundamentals (minimal revenue, ongoing losses, and cash burn) partially offset by a strong balance sheet and a favorable corporate update indicating cash runway into 2028 and advancing pipeline milestones. Technical indicators remain soft, and valuation is difficult to support due to negative earnings and no dividend.
Positive Factors
Cash runway into 2028
A ~ $209M cash position with runway into 2028 materially reduces near-term funding risk and allows Compass to advance multiple clinical milestones without immediate capital raises. This durability lets management de-risk programs, pursue data-driven partnerships, and plan commercialization steps with lower short-term dilution risk.
Negative Factors
Persistent negative free cash flow
Sustained negative operating and free cash flow (~-$49M TTM) means the company will continue consuming cash as it develops programs. Even with runway, persistent burn necessitates future financing if timelines slip, which risks dilution and constrains long-term capital allocation toward new indications or commercial investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway into 2028
A ~ $209M cash position with runway into 2028 materially reduces near-term funding risk and allows Compass to advance multiple clinical milestones without immediate capital raises. This durability lets management de-risk programs, pursue data-driven partnerships, and plan commercialization steps with lower short-term dilution risk.
Read all positive factors
Compass Therapeutics (CMPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$918.45M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue Growth-100.00%
EPS Growth-28.79%
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding180,087,920
10 Day Avg. Volume2,048,861
30 Day Avg. Volume1,958,708
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.53
Forecast
1Y Price Target
$13.50Price Target Upside164.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$1.42M
Compass Therapeutics Business Overview & Revenue Model
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development inclu...
How the Company Makes Money
Compass Therapeutics makes money primarily through the development and commercialization of its proprietary antibody therapeutics. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing...
Compass Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 850.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -72.84M | -54.87M | -48.47M | -39.75M | -80.19M |
| Net Income | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
Balance Sheet | |||||
| Total Assets | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M |
| Cash, Cash Equivalents and Short-Term Investments | 208.91M | 126.72M | 152.46M | 186.61M | 144.51M |
| Total Debt | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Total Liabilities | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M |
| Stockholders Equity | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M |
Cash Flow | |||||
| Free Cash Flow | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M |
| Operating Cash Flow | -49.14M | -44.85M | -40.62M | -34.13M | -19.67M |
| Investing Cash Flow | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M |
| Financing Cash Flow | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M |
Compass Therapeutics Technical Analysis
Negative
5.10
Price Trends
5.86
Negative
5.47
Negative
4.37
Positive
Market Momentum
-0.17
Negative
39.65
Neutral
42.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPX, the sentiment is Negative. The current price of 5.1 is below the 20-day moving average (MA) of 5.37, below the 50-day MA of 5.86, and above the 200-day MA of 4.37, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 42.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMPX.
Compass Therapeutics Risk Analysis
Compass Therapeutics disclosed 76 risk factors in its most recent earnings report. Compass Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compass Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $940.44M | -37.98 | -444.41% | ― | ― | -13.14% | |
52 Neutral | $918.45M | -12.74 | -43.61% | ― | -100.00% | -28.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $953.34M | -33.83 | -19.77% | ― | -10.26% | 144.62% | |
46 Neutral | $301.06M | -2.24 | -33.20% | ― | -23.43% | -9.84% | |
45 Neutral | $356.62M | -35.28 | -0.04% | ― | ― | -73.48% | |
39 Underperform | $75.10M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
CMPX
Compass Therapeutics
5.10
2.86
127.68%
KALV
KalVista Pharmaceuticals
18.36
7.21
64.59%
CTMX
CytomX Therapeutics
4.41
3.83
660.34%
GOSS
Gossamer Bio
0.32
-0.67
-67.81%
BCYC
Bicycle Therapeutics
4.34
-3.51
-44.71%
MNPR
Monopar Therapeutics Inc
53.29
19.86
59.41%
Compass Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Compass Therapeutics details cash runway and pipeline progress
Positive
Jan 6, 2026
On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and marketable securities balance of about $209 million as of December 31, 2025, which it expects will fund operations into 2028, and provided a broad corporate update ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.